# BioNTech SE: overview BNTX · Nasdaq · CIK 1776985 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/bntx.md) · [Financials](/companies/bntx/financials.md) · [Filings](/companies/bntx/filings.md) · [Insiders](/companies/bntx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $bn | [19.0](/filings/0001776985-24-000027.md) | [17.3](/filings/0001776985-25-000013.md) | [3.8](/filings/0001776985-26-000017.md) | [2.8](/filings/0001776985-26-000017.md) | [2.9](/filings/0001776985-26-000017.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [80.5%](/filings/0001776985-24-000027.md) | [73.0%](/filings/0001776985-25-000013.md) | [18.1%](/filings/0001776985-26-000017.md) | [(47.8%)](/filings/0001776985-26-000017.md) | [(49.0%)](/filings/0001776985-26-000017.md) | | Net margin | % | [54.2%](/filings/0001776985-24-000027.md) | [54.5%](/filings/0001776985-25-000013.md) | [24.4%](/filings/0001776985-26-000017.md) | [(24.2%)](/filings/0001776985-26-000017.md) | [(39.6%)](/filings/0001776985-26-000017.md) | | Diluted EPS | $ per share | [39.63](/filings/0001776985-24-000027.md) | [37.77](/filings/0001776985-25-000013.md) | [3.83](/filings/0001776985-26-000017.md) | [(2.77)](/filings/0001776985-26-000017.md) | [(4.70)](/filings/0001776985-26-000017.md) | | Free cash flow | $bn | [0.8](/filings/0001776985-24-000027.md) | [13.2](/filings/0001776985-25-000013.md) | [5.1](/filings/0001776985-26-000017.md) | [(0.1)](/filings/0001776985-26-000017.md) | [0.3](/filings/0001776985-26-000017.md) | - Revenue. XBRL Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:RevenueFromContractsWithCustomers. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bntx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $704.6m | 7,571,805 | | Added +1,862,565 | | [PRIMECAP MANAGEMENT CO/CA/](/funds/763212.md) | 2026-06-30 | $351.0m | 3,772,031 | | Reduced −21,680 | | [Dodge & Cox](/funds/200217.md) | 2026-06-30 | $342.2m | 3,677,591 | | Added +800 | | [FLOSSBACH VON STORCH SE](/funds/1575677.md) | 2026-06-30 | $207.1m | 2,226,138 | | Reduced −1,454,177 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $172.6m | 1,854,966 | | Added +196,813 | | [Temasek Holdings (Private) Ltd](/funds/1021944.md) | 2026-06-30 | $140.1m | 1,506,027 | | Unchanged | | [BNP PARIBAS FINANCIAL MARKETS](/funds/1166588.md) | 2026-06-30 | $122.8m | 1,319,517 | | Reduced −332,272 | | [Logos Global Management LP](/funds/1792126.md) | 2026-06-30 | $94.4m | 1,015,000 | | New +1,015,000 | | [GSK plc](/funds/1131399.md) | 2026-06-30 | $82.8m | 889,824 | | Unchanged | | [FIRST TRUST ADVISORS LP](/funds/1125816.md) | 2026-06-30 | $73.6m | 791,469 | | Reduced −48,522 | ## Recent filings [All 585 filings](/companies/bntx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 06:23 ET | [6-K](/filings/0001776985-26-000074.md) | Report of a foreign private issuer, period 2026-10-26 | 0001776985-26-000074 | | 2026-10-22 | 07:49 ET | [6-K](/filings/0001776985-26-000072.md) | Report of a foreign private issuer, period 2026-10-22 | 0001776985-26-000072 | | 2026-10-19 | 07:26 ET | [6-K](/filings/0001776985-26-000069.md) | Report of a foreign private issuer, period 2026-10-19 | 0001776985-26-000069 | | 2026-10-13 | 16:08 ET | [6-K](/filings/0001776985-26-000067.md) | Report of a foreign private issuer, period 2026-10-13 | 0001776985-26-000067 | | 2026-09-18 | 16:09 ET | [6-K](/filings/0001776985-26-000065.md) | Report of a foreign private issuer, period 2026-09-18 | 0001776985-26-000065 | | 2026-09-14 | 08:28 ET | [6-K](/filings/0001776985-26-000063.md) | Report of a foreign private issuer, period 2026-09-14 | 0001776985-26-000063 | | 2026-08-28 | 09:06 ET | [6-K](/filings/0001776985-26-000061.md) | Report of a foreign private issuer, period 2026-08-28 | 0001776985-26-000061 | | 2026-08-27 | 16:54 ET | [6-K](/filings/0001776985-26-000059.md) | Report of a foreign private issuer, period 2026-08-27 | 0001776985-26-000059 | | 2026-08-20 | 07:36 ET | [6-K](/filings/0001776985-26-000057.md) | Report of a foreign private issuer, period 2026-08-20 | 0001776985-26-000057 | | 2026-08-04 | 07:01 ET | [6-K](/filings/0001776985-26-000055.md) | Report of a foreign private issuer, period 2026-06-30 | 0001776985-26-000055 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001776985-26-000017.md), filed Mar 10, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1776985 - Tickers: BNTX - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: 2M - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 06:48 ET. No prices; not investment advice.